



NEGLECTED AND OTHER INFECTIOUS DISEASES

BILL & MELINDA GATES FOUNDATION

USAID Meeting

Washington DC

October 2008

BILL & MELINDA
GATES *foundation*


The Foundation in brief

- The Bill & Melinda Gates Foundation was founded in 2000 to help reduce inequities around the world.
- Our work begins with Bill and Melinda Gates's belief that all lives have equal value.
- The Global Health Program's objective is to ensure that lifesaving advances in health are developed and shared with those who need them most. We focus our funding on:
 - » Access to existing vaccines, drugs, and other tools to fight diseases common in developing countries.
 - » Research to develop health solutions that are effective, affordable, and practical.
- **We prioritize our work based on:**
 - » The greatest burden of disease;
 - » Existing gaps in funding and attention;
 - » Efforts that will benefit the most people (emphasis on prevention); and
 - » A balance between risk and innovation.

Little-known diseases – huge burden

Burden of diseases comparable either malaria or TB
At least 30 million DALYs annually

DALY Burden and Deaths: Major Diseases



Beyond the numbers

Painful



Stigmatizing



Debilitating



**AND IN SOME
CASES FATAL**

Theory of Change

1) Invest strategically in:

- Drug treatments
- Vaccines
- Diagnostics and new biomarkers
- Vector control tools and strategies
- Implementation strategy

And advocate for:

- Resources for Neglected Diseases
- Success of FDA voucher program
- Global political support

2) Fulfill near-term objectives...

- Prove drug, vaccine, diagnostic and vector control safety and effectiveness
- Demonstrate impact
- Integrate systems of delivery
- Establish monitoring and indicators of progress

- Mobilize support
- Enhance country planning activities
- Build political will
- Encourage broad participation

3) Achieve measurable, long-term goals

Eradication

Elimination

Control

Reduce the suffering, deaths and burden on global poverty

So what are we doing?-

Strategic investment in removing barriers to success and to increase impact of programs

■ **Investing in new tools**

- » New drugs- sleeping sickness, leishmaniasis
- » New vaccines- hookworm, Sleeping sickness, cysticercosis
- » New and improved diagnostics- LF, sleeping sickness, trachoma

■ **Investing in better use of existing tools**

- » Evaluation and role out and of strategies- LF, oncho, schisto, trachoma, STH
- » OR on integration of strategies
- » OR disease specific- LF, oncho elimination, trachoma

New investments under consideration this year

New tools

- Schisto diagnostics

Improved use of existing tools

- Schisto OR
- Increasing investments in integrated NTD programs and partnership
- Successful Guinea worm eradication
- Azithromycin treatment impact
- OR funds macrofilaricide delivery (doxycycline) and LF elimination impact on oncho

The future

- We have a 5 year strategy which has recently been approved with ongoing commitment
- Will be presenting our NTD and malaria strategy at ASTMH in New Orleans
- Funding complement and coordinate with other donors (drug donation, implementation and disease specific donations)
- Enhance and expand impact, buy-in and partnerships (who and how we fund to meet country needs)